• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Catholic Review

Catholic Review

Inspiring the Archdiocese of Baltimore

Menu
  • Home
  • News
        • Local News
        • World News
        • Vatican News
        • Obituaries
        • Featured Video
        • En Español
        • Sports News
        • Official Clergy Assignments
        • Schools News
  • Commentary
        • Contributors
          • Question Corner
          • George Weigel
          • Elizabeth Scalia
          • Michael R. Heinlein
          • Effie Caldarola
          • Guest Commentary
        • CR Columnists
          • Archbishop William E. Lori
          • Rita Buettner
          • Christopher Gunty
          • George Matysek Jr.
          • Mark Viviano
          • Father Joseph Breighner
          • Father Collin Poston
          • Robyn Barberry
          • Hanael Bianchi
          • Amen Columns
  • Entertainment
        • Events
        • Movie & Television Reviews
        • Arts & Culture
        • Books
        • Recipes
  • About Us
        • Contact Us
        • Our History
        • Meet Our Staff
        • Photos to own
        • Books/CDs/Prayer Cards
        • CR Media platforms
        • Electronic Edition
  • Advertising
  • Shop
        • Purchase Photos
        • Books/CDs/Prayer Cards
        • Magazine Subscriptions
        • Archdiocesan Directory
  • CR Radio
        • CR Radio
        • Protagonistas de Fe
  • News Tips
  • Subscribe
Mifepristone, the first medication in a chemical abortion, is prepared for a patient at Alamo Women's Clinic in Carbondale, Ill., April 20, 2023. The Justice Department and the manufacturer of an abortion drug asked the U.S. Supreme Court Sept. 8 to overturn a lower court ruling that would limit access to the drug, setting the stage for the high court to weigh in on the future of the drug's availability. (OSV News photo/Evelyn Hockstein)

Supreme Court is asked to weigh in on future of abortion pill

September 13, 2023
By Kate Scanlon
OSV News
Filed Under: Feature, News, Respect Life, Supreme Court, World News

WASHINGTON (OSV News) — The Justice Department and the manufacturer of an abortion drug asked the U.S. Supreme Court Sept. 8 to overturn a lower-court ruling that would limit access to the drug, setting the stage for the high court to weigh in on the future of the drug’s availability.

A coalition of pro-life opponents of mifepristone, the first of two drugs used in a medication or chemical abortion, previously filed suit in an effort to revoke the U.S. Food and Drug Administration’s approval of the drug, arguing the government violated its own safety standards when it first approved the drug in 2000.

However, proponents argued mifepristone poses statistically little risk to women using it for abortion early in pregnancy and claim the drug is being singled out for political reasons.

In its filing on behalf of the FDA, the Justice Department called the appeals court ruling an “unprecedented decision,” arguing its logic “would threaten to severely disrupt the pharmaceutical industry and prevent FDA from fulfilling its statutory responsibilities according to its scientific judgment.”

The filing argued the drug is safe and that “study after study” has shown “serious adverse events are exceedingly rare” when mifepristone is taken under the approved conditions. The filing added, “For many patients, mifepristone is the best method to lawfully terminate their early pregnancies.”

It stated that revoking approval of the pill “would be damaging for women and health care providers around the Nation.”

But in a statement, Erik Baptist, senior counsel for Alliance Defending Freedom, which is representing the pro-life coalition challenging mifepristone’s approval, said the FDA “has been entrusted to serve as the nation’s gatekeeper of legal drugs.”

“By repeatedly and unlawfully removing critical safeguards in the chemical abortion regimen, the FDA has failed to protect the safety of women and girls,” he said. “Two courts have now held the FDA accountable for the damage it has done to the rule of law and the harm it has caused to countless girls and women. We hope the Supreme Court does the same.”

Earlier this year, the Supreme Court blocked a lower court’s restrictions on mifepristone, leaving the abortion pill on the market while litigation proceeds. That decision froze the lower court’s ruling to stay the FDA’s approval of the drug.

The Justice Department and Danco, the pharmaceutical company that manufactures mifepristone, previously asked the Supreme Court to intervene in the case after an appeals court allowed portions of the ruling by U.S. District Judge Matthew Kacsmaryk to take effect.

In a Sept. 8 statement, Danco said it “continues to be at the forefront of this fight and is working closely with the reproductive rights community and pharmaceutical industry to support the changes made by FDA.”

Should the Supreme Court take the case, it would likely be added to its docket in its coming term.

The two-drug chemical abortion regimen is currently legal in some form in 36 states and the District of Columbia. It is permitted in 21 states, but with some additional restrictions in the remaining 15, according to data from the Guttmacher Institute, which supports abortion access.

The Catholic Church opposes abortion, teaching that all human life is sacred from conception to natural death and that society must extend support to mothers and children. Earlier this year, Bishop Michael F. Burbidge of Arlington, chairman of the U.S. Conference of Catholic Bishops’ Committee on Pro-Life Activities, denounced Biden administration’s attempts to loosen regulations around the abortion bill, saying the U.S. bishops “decry the continuing push for the destruction of innocent human lives and the loosening of vital safety standards for vulnerable women.”

A link to the Justice Department’s filing is here: https://s3.documentcloud.org/documents/23945337/usfda-et-al-v-alliance-for-hippocratic-medicine-et-al-petition.pdf.

Read More Respect Life

Illinois pitching for funds to shore up abortion tourism denounced as ‘macabre’

‘Radical’ abortion amendment passes Virginia General Assembly despite pro-life advocacy

Church has opposed artificial reproduction for nearly century, says author of ‘IVF is Not the Way’

Trump administration asks federal court to pause Louisiana’s abortion pill challenge

Speakers, attendees at OneLife LA push for greater respect for life: ‘Everyone is a blessing’

Hispanic Pro-Life Conference: ‘We must unite our voices’ against abortion

Copyright © 2023 OSV News

Print Print

Primary Sidebar

Kate Scanlon

Click here to view all posts from this author

For the latest news delivered twice a week via email or text message, sign up to receive our free enewsletter.

| MOST POPULAR |

  • New vision ahead for pastoral councils 

  • In National Prayer Breakfast address, Trump backs Noem after Minneapolis fallout

  • Deacon Lee Benson, who ministered in Harford County, dies at 73

  • Archbishop Lori joins local clergy decrying violence connected to immigration enforcement

  • Silence in place of homily at daily Mass

| Latest Local News |

Catholic Charities strengthens Fugett Center offerings with partnerships

Catholics asked to step up for Maryland’s Virtual Catholic Advocacy Day

New vision ahead for pastoral councils 

Sister Joan Elias, leader in Catholic education, dies at 94

Speaker and musician Nick De La Torre to lead pre-Lenten mission in Frederick County

| Latest World News |

Two major medical groups back limits on gender transition procedures for minors

Pope Leo XIV urges Christian formators to learn from ‘spiritual giants’ like Augustine

Pope Leo XIV meets leaders of chastity apostolate for Catholics with same-sex attractions

SSPX leader to meet Cardinal Fernández after announcing unauthorized bishop consecrations

Bishops call Catholics to prayer, action amid U.S. immigration violence, rhetoric

| Catholic Review Radio |

Footer

Our Vision

Real Life. Real Faith. 

Catholic Review Media communicates the Gospel and its impact on people’s lives in the Archdiocese of Baltimore and beyond.

Our Mission

Catholic Review Media provides intergenerational communications that inform, teach, inspire and engage Catholics and all of good will in the mission of Christ through diverse forms of media.

Contact

Catholic Review
320 Cathedral Street
Baltimore, MD 21201
443-524-3150
mail@CatholicReview.org

 

Social Media

  • Facebook
  • Instagram
  • Twitter
  • YouTube

Recent

  • Two major medical groups back limits on gender transition procedures for minors
  • Catholic Charities strengthens Fugett Center offerings with partnerships
  • Pope Leo XIV urges Christian formators to learn from ‘spiritual giants’ like Augustine
  • Pope Leo XIV meets leaders of chastity apostolate for Catholics with same-sex attractions
  • Pope Leo denounces human trafficking as a ‘crime against humanity’
  • SSPX leader to meet Cardinal Fernández after announcing unauthorized bishop consecrations
  • Bishops call Catholics to prayer, action amid U.S. immigration violence, rhetoric
  • Church can help sports by flexing values, strengthening human dignity, pope says
  • Olympics 2026: Milan Archdiocese invites youth to live Olympic values, not just watch

Search

Membership

Catholic Media Assocation

Maryland-Delaware-DC Press Association

The Associated Church Press

© 2026 CATHOLIC REVIEW MEDIA, ALL RIGHTS RESERVED